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Abstract Mutations in the HFE gene result in iron
overload and can produce hereditary hemochromatosis
(HH), a disorder of iron metabolism characterized by
increased intestinal iron absorption. Dietary quality, alco-
holism and other life-style factors can increase the risk of
iron overload, especially among genetically at risk pop-
ulations. Polymorphisms of the HFE gene (C282Y, H63D
and S65C) were measured together with serum ferritin (SF),
transferrin saturation (TS) and hemoglobin, to measure iron
status, in randomly-selected healthy subjects living in the
Spanish Mediterranean coast (n=815; 425 females, 390
males), 18 to 75 years of age. The intake of dietary
components that affect iron absorption was calculated from
3-day dietary records. The presence of C282Y/H63D
compound heterozygote that had a prevalence of 2.8% in
males and 1.2% in females was associated with an elevated
TS and SF. No subject was homozygous for C282Y or
S65C. The C282Y heterozygote, H63D heterozygote and
homozygote and H63D/S65C compound heterozygote
genotypes were associated with increased TS relative to
the wild type in the general population. These genotypes
together with the alcohol and iron intake increase the
indicators of iron status, while calcium intake decreases
them. We did not observe any affect of the S65C
heterozygote genotype on these levels. All the HFE
genotypes except for the S65C heterozygote together with
the alcohol, iron and calcium intake affect the indicators of
iron status. The C282Y/H63D compound heterozygote
genotype has the higher phenotypic expression in our
Spanish Mediterranean population.
Keywords Ironoverload.HFEgene.C282Yvariant.H63D
variant.S65Cvariant.Mediterranean diet
Abbreviation
HH Hereditary hemochromatosis
FS Serum ferritin
TS Transferrin saturation
BMI Body mass index
MLR Multiple linear regression model
Background
Iron overload can be associated with certain genetic
mutations and environmental factors. The HFE gene,
together with other biologically active compounds, regu-
lates the intestinal absorption of iron [1, 2]. There have
been three common variants detected in this gene, C282Y,
H63D and S65C, which have been related to the suscep-
tibility to iron overload. Studies in Europe have reported
the prevalence of the homozygous C282Y genotype as
<1.5% and that of the heterozygous genotype as <29%; the
highest rates occur in northern Europe [3, 4]. Homozygotes
and heterozygotes for the H63D mutation constitute <8%
and <38.8%, respectively, in the populations studied to-date
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DOI 10.1007/s00277-010-0901-9in Europe [4]. These polymorphisms are most prevalent in
southern Europe. The prevalence of the C282Y/H63D
compound heterozygote is <4% [4].
The prevalence of the H63D in our population is
elevated, being present in heterozygote form in 32.3% and
in homozygote form in 4.8% [5]. The C282Y mutation is
less prevalent, so far being found only in heterozygous
form in 4.3% of our population [4–6]. The S65C mutation
is less well studied but, as well, has been associated with
alterations in the mechanisms of intestinal iron absorption
[7, 8]. We have not detected any homozygous cases, and
the heterozygous form is present in 2% of the population.
The compound forms of these three mutations are present in
2.6% [5].
The biochemical phenotypic expression of the H63D
(homozygote and heterozygote) and of the C282Y
(heterozygotes) genotypes is much lower than that in
the C282Y homozygote or in the compound C282Y/
H63D genotypes [9, 10]. Even though these genotypes do
not have high penetration at the biochemical level, it is
possible that body levels of iron in affected persons can be
higher than normal, and be potential risks for some
diseases. Several authors have postulated that levels of
iron near the upper limit of normal are associated with
pathological processes including cellular oxidation, car-
diovascular disease and cancer [10–18]. However, these
relations have not always been observed in populations,
such being the case of the French studied in the
SUVIMAX intervention study [19, 20].
Dietary quality, alcoholism and other life-style factors
can increase the risk of iron overload, especially among
genetically at risk populations [21, 22], and yet there are no
data on these effects in our population. The main objective
of this paper was to fill this gap.
Methods
The sample was randomly drawn from the local govern-
ment census of three communities in the Mediterranean
region of Tarragona (N.E. Spain). The sample consisted of
individuals of Caucasian origin, stratified by age and
gender, reflecting its distribution in the study area.
Exclusion criteria were: inability to understand the charac-
teristics of the study, suffering severe disease that would
impair participation, pregnancy, or being within 6 months
post-partum. The study was approved by the Ethics
Committee of the Sant Joan University Hospital and the
Jordi Gol Gorina Foundation.
Letters of invitation to participate in the study were sent
to a total of 1,325 people. Willingness to participate was
confirmed by phone call. If someone refused or could
not be contacted following three different phone calls (at
different times on different days), they were replaced by the
next available candidate of the same age and sex on the list.
A total of 815 healthy subjects (425 female, 390 males)
between 18 and 75 years were studied.
All the individuals provided written informed consent
according to the Declaration of Helsinki. Subjects selected
for participation were interviewed and the following data
were recorded: demographic characteristics, data on any
current pathology, medications and iron supplements used
in the last year, anthropometric measurements (height and
weight) and life-style habits such as smoking, ingestion of
alcoholic beverages, and physical activity. Food intake was
evaluated using the diary recall method over three non-
consecutive days including a weekend or a holiday [23].
Body mass index (BMI) was calculated as weight/height
squared.
A venous blood sample was drawn from subjects into
two 10 ml. vacutainer tubes: one was containing EDTA for
the measurement of the hematological profile and for DNA
extraction, and the other without anticoagulant for serum
biochemistry analyses. All the samples were extracted at
the same time (between 8 and 8.30 h) with the subjects
having fasted since the previous evening.
C282Y (G845A), H63D (C187G) [24] and S65C
(A193T) [7] mutations of the HFE gene were measured
using the polymerase chain reaction (PCR). Absence of
these three mutations defined the wild-type genotype.
Serum iron (μmol/L) and serum transferrrin (g/L) were
measured using commercial kits (ITC Diagnostics and
Biokit S.A., Barcelona). Serum ferritin (SF; μg/L) was
measured immuno-turbidimetrically [25]. The transferrin
saturation index was calculated as reported [26]. Since
inflammation and infection can elevate SF levels, these
were adjusted by C-reactive protein levels (CRP; Biokit
S.A., Barcelona, Spain). Ferritin log transformed values
(log-ferritin) were used in the statistical analyses because of
its skewed distribution. Blood hemoglobin (g/dl) was
measured in duplicate with a Coulter GENS analyzer
(Coulter, Hialeah, FL).
The extraction and storage of blood samples followed
a protocol established and accepted by international
studies. The method for assessing habitual food intake
(the dietary recall method) has been validated interna-
tionally and shown to be the method with the appropriate
level of accuracy to enable assessments of nutritional
status [27].
All data were analyzed using the SPSS package for
Windows (version 17.0). t Test was used for comparison of
continuous data and Pearson’s chi-square or Fisher’s test to
compare categorical data. Two multiple linear regression
(MLR) models were applied to explain the effect of the
genotypes on the measured values of iron status. TS was
the dependent variable in one, and log-ferritin was the
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segregated into six groups: (a) C282Y heterozygotes; (b)
H63D heterozygotes; (c) S65C heterozygotes; (d) H63D
homozygotes; (e) C282Y/H63D compound heterozygotes
and (f) H63D/S65C compound heterozygotes. Dummy
variables were created with each of these six groups in
order to compare each of them with the wild-type genotype.
In both models the “ENTER” method was used for the
dummy genetic variables (no/yes) and “STEPWISE” meth-
od for gender (female; male), age (years), BMI (Kg/m
2),
smoking habit (cigarettes/day), level of physical activity
(h/week), Iron supplements intake (no, yes), and the dietary
variables related to iron metabolism, i.e., energy (Joules),
iron (mg/day), proteins (g/day), fiber (g/day), calcium
(mg/day), vitamin C (mg/day), and alcohol intake (g/day).
Subsequently, these same models were applied separately for
each gender and, as such, gender was not entered as a
variable in the analysis. The level of statistical significance
was set at p<0.05.
Results
Table 1 contains the means of the TS and FS distribution
segregated according to HFE genotypes and gender. In
males, the mean values of TS were significantly elevated in
the C282Y/H63D compound heterozygotes relative to wild
type. In females, the mean TS was also elevated in the
C282Y heterozygotes, H63D heterozygotes, and homozy-
gotes and again in the C282Y/H63D compound hetero-
zygotes genotypes relative to wild type. When the weighted
mean of TS of all subjects with any HFE mutation (44.5%
males and 47.2% females) is compared with that of the
wild-type genotype, the subjects with these mutations,
independent of gender, showed higher concentrations of
TS. In contrast, we did not observe statistically significant
differences in serum ferritin levels (Table 1).
Three men and 22 women were taking iron supple-
ments, and had SF of 37.8 μg/L and TS of 27.1%
compared with SF of 102.7 μg/L and TS of 34.1% in the
Table 1 Biochemical parameters of iron segregated with respect to HFE genotypes and gender in the study population
Subjects (%) HFE genotype Hemoglobin
(g/dl)
Transferrin saturation (%) Serum ferritin (μg/L)
C282Y H63D S65C Mean (SD) Mean (SD) >45 (%)
a Geometric mean (SD)
b >100 (%)
a >150 (%)
a >200 (%)
a
Males, n=390
55.5 −/−− /−− /− 15.3 (.9) 37.7 (20.8) 22.7 105.6 (2) 59.5 27.9 16.7
2.3 −/−− /− +/− 15.4 (1.1) 40.9 (12.2) 33.3 76.9 (2.5) 44.4 22.2 11.1
3.9 +/−− /−− /− 15.5 (1.0) 41.9 (14.5) 26.7 99.8 (2.2) 73.3 46.7 13.3
31.6 −/− +/−− /− 15.5 (1.0) 39.7 (13.3) 28.5 109.9 (2.2) 64.2 36.6 25.2*
3.3 −/− +/+ −/− 15.2 (1.0) 40.0 (20.9) 38.5 101.6 (2.5) 84.6 38.5 15.4
0.5 −/− +/− +/− 16.1 (.9) 65.9 (42.9) 50 187.8 (1.7) 100 50 50
2.8 +/− +/−− /− 15.7 (.9) 53.4 (19)* 63.6** 143.5(2.6) 63.6 54.5* 36.4
100 15.4 (1.0) 39.3 (18.5) 26.7 106.9(2.1) 62.1 32.4 19.7
44.5
c 15.5 (1.0) 41.2 (15.2)* 31.8* 108.5(2.2) 65.9 38.2* 23.7*
Femalesn=425
52.8 −/−− /−− /− 13.3 (1.0) 26.7 (11.2) 6.3 33.1 (2.3) 9 4.5 2.2
1.7 −/−− /− +/− 12.9 (1.1) 26.5 (11) 0 28.1 (2.5) 14.3 0 0
4.7 +/−− /−− /− 13.9 (1.2) 32.7(11.9)* 10.5 48.6 (2.1) 15.8 5.3 5.3
32.8 −/− +/−− /− 13.4 (.9) 30.6 (14.5) ** 11.5 37.2 (2.1) 11.6 2.9 2.2
6.1 −/− +/+ −/− 13.9 (.9) 34.9 (13.1)** 15.4 37.7 (1.7) 0 0 0
0.7 −/− +/− +/− 13.9 (.7) 26.8 (10.3) 0 54.6 (1.7) 0 0 0
1.2 +/− +/−− /− 13.9 (.8) 40.5 (5.4) ** 20 47.2 (2.2) 20 20 0
100 13.4 (1.0) 28.9 (12.7) 8.7 35.6(2.2) 10 4 2.4
47.2
c 14.2(9.1) 31.4 (13.8)*** 11.6* 38.3(2.1) 10.6 3 2
(−) indicates HFE wild type, (+) indicates mutated allele, SD standard deviation
*p<0.05 **p<0.01 ***p<0.001 vs versus wild type (t student, χ
2 Pearson’s or Fisher’s test)
aSubjects (%)
bGeometric mean (SD) antilog values
cSubjects with mutations in HFE gene
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and TS, respectively).
When diet and other life style variables besides HFE
polymorphisms were included in an analysis using MLR in
order to determine the influence of HFE mutations on TS
and SF values (Table 2), the TS was found significantly
increased with all the HFE genotypes except for the S65C
heterozygotes. The following were positively related in the
model: iron intake, alcohol intake, tobacco habit, and male
gender, while calcium intake was inversely related. Table 2
only shows the significant results. The same MLR model
applied only to females showed a significant increase in TS
in the presence of the C282Y heterozygote (β, 6.43; SE,
3.03; p, 0.035), H63D heterozygote (β, 4.13; SE, 1.39;
p, 0.003) and homozygote (β, 8.43; SE, 2.61; p, 0.001) and
the C282Y/H63D compound heterozygote genotypes
(β, 13.11; SE, 5.59; p, 0.02). Tobacco habit was positively
related (β, 0.21; SE, 0.08; p, 0.013). The same MLR model
applied only to males showed that TS was increased
significantly with the C282Y/H63D (β, 13.21; SE, 6.59;
p, 0.046) and H63D/S65C (β, 27.83; SE, 12.98; p, 0.033)
compound heterozygotes. Iron intake was positively related
to TS (β, 0.97; SE, 0.24; p<0.001) whether the 22 women
and three men that were ingesting iron supplements were
included or not in the analysis (data not shown).
In the overall population sample, log serum ferritin (log-
FS) was significantly increased in the presence of the
C282Y/H63D compound mutations, and in relation to
alcohol consumption, age and male gender. Log-SF was
negatively related to calcium intake. MLR applied only to
females showed log-SF significantly increased with smok-
ing (β, 0.01; SE, 0.005; p, 0.003; %v, 1.01) and increasing
age(β, 0.02; SE, 0.002; p<0.001; %v, 2.02), and decreased
with the intake of calcium (β, −3.5e-4; SE, 1.15e-4;
p, 0.002; %v, 0.04). In males, log-FS increased significantly
with C282Y/H63D compound genotypes (β, 0.44; SE,
0.24; p, 0.05, %v, 55.27) and with the consumption of
alcohol (β, 0.008; SE, 0.002; p<0.001; %v, 0.8), and
decreased with the consumption of calcium (β, −2.5e-4;
SE, 1.06e-4; p, 0.015; %v, 0.02). The influence of these
variables on the population with the wild type in HFE
genes independent of gender did not reach significance.
Consistently, however, calcium and fiber intake correlate
negatively with both TS and SF among males with HFE
polymorphisms. Again, the exclusion of the three men and
the 22 females ingesting iron supplements did not change
the results (data not shown).
Discussion
Many studies have analyzed the relation between HFE
mutations and iron status [9, 28–36]. There are a few other
recent studies that explore external factors that interact with
HFE mutations in modifying the phenotypic expression in
indicators of iron status of the genetic HFE makeup [37,
Table 2 Effect of mutations in the HFE gene on biochemical levels of transferrin saturation and serum ferritin (log-FS) in the overall population
sample (n=815)
Transferrin saturation Serum ferritin (log-FS)
β coeff. SE p-value β coeff. SE p value %v
C282Y/ WT 5.75 2.75 0.037 0.19 0.12 0.12
H63D/ WT 3.00 1.24 0.015 0.06 0.05 0.261
S65C/ WT 0.77 4.05 0.850 -0.16 0.18 0.361
H63D /H63D 7.26 2.66 0.006 0.01 0.11 0.888
C282Y/H63D 16.4 4.2 <0.001 0.32 0.18 0.049 37.7
H63D/S65C 18.28 7.73 0.018 0.54 0.34 0.117
Gender (female; male) 8.04 1.27 <0.001 0.97 0.05 <0.001 163.7
Age (years) 0.01 0.002 <0.001 1.01
Iron (mg/day) 0.58 0.17 0.001
Calcium (mg/day) −0.004 0.002 0.042 −2.5e
−4 7.9e
−5 0.002 0.02
Alcohol (g/day) 0.069 0.03 0.037 0.007 0.001 <0.001 0.7
Tobacco (cig/day) 0.17 0.06 0.007
R2
c ¼ 15:2 R2
c ¼ 42:4
F11.756=14.9 p<0.001 F10.749=56.79 p<0.001
Serum ferritin adjusted for C reactive protein and log transformed (log-FS). Adjusted for gender (female/male), age (years), BMI (Kg/ m
2), energy
(Joules), diet iron (mg/day), proteins (g/day), fiber (g/day), calcium (mg/day), vitamin C (mg/day), alcohol (g/day), smoking habit (cigarettes/day),
level of physical activity (h/week) and iron supplements intake (no, yes)
WT wild type, SE standard error, %v percentage of variation
770 Ann Hematol (2010) 89:767–77338]. However, to our knowledge, the present study is the
only one to evaluate the impact of the three common
variants of the HFE gene, the diet and life style variables on
indicators of iron status in a sample representative of the
general Spanish Mediterranean population. The prevalence
of S65C variant in a general population and its relation with
iron status has scarcely been investigated. The S65C
heterozygote genotype is infrequent in our and in most
European populations, and, contrary to Mura et al’s. [7]
results appear to have little influence on iron status based
on our MLR although a larger sample size is needed to
support that.
The different effects of HFE mutations on TS and SF
found in our MLR analyses concur with those observed by
other investigators [28, 39] in showing that individual
carriers of heterozygous HFE mutations have a greater
susceptibility to increased TS, and possibly of iron overload
(Table 2) but to levels that are not associated with organ
damage [40, 41]. The influence of single HFE heterozygous
or even homozygous mutations for H63D on SF is not
significant independent of gender (Table 2). However, the
compounded heterozygous C282Y/H63D genotype dis-
plays the most significant elevation of TS and SF values,
in both women, and men. The phenotypic expression of the
compounded heterozygous mutations involving the H63D
mutation suggests an important role in expression or
penetrance of the other mutations. The H63D variant has
a lower effect on iron status, but its repercussion is very
important due to its elevated frequency (38.2%) [5, 42]. As
in our population, an elevated prevalence of this mutation
has been observed in other populations in the southern
Europe [10].
It is interesting to note that the phenotypic expression
of H63D homozygote, C282Y and H63D heterozygote
genotypes appear significantly only in women, suggest-
ing HFE-gender interactions that should be explored
further. The MLR models used in the analysis of our
data enabled us to estimate the effect of HFE mutations
on the levels of iron in our ostensibly healthy general
population, independent of the contributions of diet and
other life-style factors. In the overall population the
compound genotypes are associated with a 16.4%
(C282Y/H63D) and 18.3% (H63D/S65C) increase in
the TS concentrations relative to the subjects with wild
type HFE. Also, 37.7% of the variation in serum ferritin
concentration is explained by the heterozygous com-
pound C282Y/H63D.
It is important to note that elevations in TS are more
evident in men with HFE compound polymorphisms
involving H63D variant than elevations in SF. Organ
damage associated with hemochromatosis occurs only
when both TS and SF are significantly elevated, the risk
of which appears to be somewhat higher in these cases [4].
Unfortunately, the small number of cases limits the strength
of our interpretations.
Based on the TS distributions an important percentage of
our subjects (6.3% of females and 22.7% of males) with the
wild-type genotype as well as those with the C282Y, H63D,
and S65C genotypes have elevated values of TS (>45%)
and SF (between 110 and 200 μg/L in 2.8% of females, and
between 200 and 300 μ/L in 7.4% of males). These results
are higher than those found in a study carried out in a
Danish male general population [38], and indicate that, as is
known, there are other contributory factors in iron
homeostasis not discussed in this paper but that can
significantly affect the indicators of iron nutrition with
respect to the HFE mutations in our population. We
observed that dietary factors modulated the values of SF
and TS in the expected manner and could, increase or
decrease iron absorption and body iron (total iron intake
increased and calcium decreased TS and SF values).
However, dietary heme iron intake did not enter signifi-
cantly into the equation (data not shown). This contrast
with several reports suggesting that heme iron ingestion
affect iron status and absorption in individuals with HFE
mutations [34, 38, 43], however heme iron intake in our
population was moderate (mean, 3.6 mg/day). It would
appear that there is a decrease in the control of iron
absorption in subjects heterozygous for C282Y [44],
allowing its absorption from diets rich in bioavailable iron.
We do not know if this mechanism applies equally in other
HFE mutations [10, 45, 46]. In agreement with other
investigations [38, 47, 48], alcohol consumption reported
by our population resulted in increased TS and SF values.
The combined effect of diet and mutations of the HFE
gene suggests prudence in the politics of iron fortification
of foods given that our Mediterranean diet is a good source
of bio-available iron [49] inspite of controversies on this
issue. On the other hand, the consistent lower TS and SF
related to the intake of dietary calcium and fiber among
males with HFE mutations may be considered a recom-
mended dietary intervention.
In conclusion, the C282Y/H63D compound heterozy-
gote genotype is associated with an increase in TS and SF
values compared to the wild type. The C282Y heterozy-
gote, H63D heterozygote and homozygote and H63D/S65C
compound genotypes are related to increase in TS, but do
not affect SF levels. The S65C heterozygote genotype does
not significantly modify TS and SF. There is an interaction
between the phenotypic manifestation on TS and SF of
HFE mutations and gender. Iron intake as well as alcohol
consumption increase, and dietary calcium and fiber cause a
decrease in the indicators of iron status in the population,
some effects differing by gender. The high prevalence of
HFE mutations in our population together with the high
bio-availability of iron in our Mediterranean diet calls for
Ann Hematol (2010) 89:767–773 771prudence in introducing measures aimed at increasing iron
intake in all the population. High calcium and fiber intakes
and abstinence from alcohol should be recommended for
males with HFE mutations. Studies with larger samples
should explore further these results.
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